BIOMARIN PHARMACEUTICAL INC: common-stock repurchase payments
Common-stock repurchase payments for BIOMARIN PHARMACEUTICAL INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BIOMARIN PHARMACEUTICAL INC financial histories
What this measure means
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
Exact concept: us-gaap:PaymentsForRepurchaseOfCommonStock. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-01-01 to 2022-12-31. The SEC response was captured on 2026-09-20.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2022-01-01 | 2022-12-31 | 0 | USD | 2023-02-27 | 10-K · 0001048477-23-000009 |
| 2021-01-01 | 2021-12-31 | 0 | USD | 2023-02-27 | 10-K · 0001048477-23-000009 |
| 2020-01-01 | 2020-12-31 | 50,000,000 | USD | 2023-02-27 | 10-K · 0001048477-23-000009 |
| 2019-01-01 | 2019-12-31 | 0 | USD | 2022-02-25 | 10-K · 0001048477-22-000012 |
| 2018-01-01 | 2018-12-31 | 0 | USD | 2021-02-26 | 10-K · 0001048477-21-000008 |
Related financial histories
- BIOMARIN PHARMACEUTICAL INC: total assets
- BIOMARIN PHARMACEUTICAL INC: total liabilities
- BIOMARIN PHARMACEUTICAL INC: stockholders equity
- BIOMARIN PHARMACEUTICAL INC: cash and cash equivalents
- BIOMARIN PHARMACEUTICAL INC: net income or loss
- BIOMARIN PHARMACEUTICAL INC: operating cash flow
- BIOMARIN PHARMACEUTICAL INC: capital expenditure payments
- BIOMARIN PHARMACEUTICAL INC: revenue
- BIOMARIN PHARMACEUTICAL INC: contract revenue excluding tax
- BIOMARIN PHARMACEUTICAL INC: financing cash flow
- BIOMARIN PHARMACEUTICAL INC: investing cash flow
- BIOMARIN PHARMACEUTICAL INC: retained earnings or deficit
- BIOMARIN PHARMACEUTICAL INC: basic weighted-average shares
- BIOMARIN PHARMACEUTICAL INC: diluted weighted-average shares
- BIOMARIN PHARMACEUTICAL INC: basic earnings per share
- BIOMARIN PHARMACEUTICAL INC: diluted earnings per share
- BIOMARIN PHARMACEUTICAL INC: income tax expense or benefit
- BIOMARIN PHARMACEUTICAL INC: net property, plant and equipment
- BIOMARIN PHARMACEUTICAL INC: share-based compensation expense
- BIOMARIN PHARMACEUTICAL INC: operating income or loss
- BIOMARIN PHARMACEUTICAL INC: current assets
- BIOMARIN PHARMACEUTICAL INC: interest expense
- BIOMARIN PHARMACEUTICAL INC: current liabilities
- BIOMARIN PHARMACEUTICAL INC: current accounts payable
- BIOMARIN PHARMACEUTICAL INC: goodwill carrying amount
- BIOMARIN PHARMACEUTICAL INC: net finite-lived intangible assets
- BIOMARIN PHARMACEUTICAL INC: net current accounts receivable
- BIOMARIN PHARMACEUTICAL INC: net inventory
- BIOMARIN PHARMACEUTICAL INC: cost of revenue
- BIOMARIN PHARMACEUTICAL INC: selling, general and administrative expense
- BIOMARIN PHARMACEUTICAL INC: research and development expense
Inspect the source
- Entity
- BIOMARIN PHARMACEUTICAL INC / CIK 0001048477
- Captured
- 2026-09-20T05:16:57.630Z
- SEC response SHA-256
6bbba50e8b979af7a921a05188b4c51294e68e48d171ac508612bd4700bc19cd
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001048477.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))